STRATEGIES FOR MINIMIZING CORTICOSTEROID EXPOSURE IN SLE

Zahir Amoura. French National Reference Center for SLE and APS, Pitié-Salpêtrière Hospital, Paris, France

10.1136/lupus-2021-la.15

Glucocorticoids (GCs) play a central role in the treatment of active systemic lupus erythematosus (SLE). Long-term GC-related side effects (i.e., infections, diabetes mellitus, cataract, osteoporosis, gastrointestinal bleeding and cardiovascular disease), leading to the development of irreversible organ damage, mean that clinicians must develop strategies for minimizing GC exposure in SLE.¹ Initiation of oral GC should be avoided, especially when there are effective therapeutic alternatives as for cutaneous and articular manifestations. In patients with lupus nephritis, starting GC with a medium prednisone dose (0.5 mg/kg/day) is as effective as high-dose dose (1 mg/kg/day) prednisone.¹ Use of intravenous methylprednisolone (MP) pulses (usually 250–1000 mg/day for 3 days) may allow for a lower starting dose and faster tapering of oral GC.^{2–3} Early initiation of immunosuppressive drugs can facilitate a more rapid GC tapering and may prevent SLE flares.⁴ Long-term GC administration with doses of ≤ 5 mg/day prednisone produces an acceptably low level of harm, with the exception of patients at high cardiovascular risk who may require preventive measures.⁵ Withdrawal of low dose prednisone is also recommended by EULAR, when possible,¹ but recent data suggest that this exposes SLE patients to an increased risk of flare, whereas its long-term maintenance is not associated with increased damage scores.⁶

Learning Objectives

- Describe strategies for minimizing corticosteroid dose at treatment initiation for lupus nephritis, cutaneous lupus and lupus arthritis
- Describe strategies for minimizing corticosteroid exposure when SLE remission has been reached

REFERENCES

1. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis*. 2019;**78**(6):736–45.
2. Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, et al. Restrictive Use of Oral Glucocorticoids in Systemic Lupus Erythematosus and Prevention of Damage Without Worsening Long-Term Disease Control: An Observational Study. *Arthritis Care Res (Hoboken)*. 2018;**70**(4):582–91.
3. Ruiz-Irastorza G, Petri M, Gordon C, Khamashta M. Managing lupus nephritis in pregnant women: comment on the article by Hahn, et al. *Arthritis Care Res (Hoboken)*. 2013;**65**(8):1391–2.
4. Pego-Reigosa JM, Cobo-Ibanez T, Calvo-Alen J, et al. Efficacy and safety of non-biologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. *Arthritis Care Res (Hoboken)*. 2013;**65**(11):1775–85.
5. Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. *Ann Rheum Dis*. 2016;**75**(6):952–7.
6. Mathian A, Pha M, Haroche J, et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. *Ann Rheum Dis*. 2020;**79**(3):339–46.

TARGETING REMISSION AND LOW DISEASE ACTIVITY IN SLE

Professor Andrea Doria. University of Padova, Italy

10.1136/lupus-2021-la.16

Remission and low disease activity (LDA) are the most important targets to achieve in systemic lupus erythematosus (SLE) management.^{1–5} In this process, the first target we should try to achieve is remission and when remission cannot be achieved we should aim for clinical LDS.³ Nowadays, achieving remission or LDA is not uncommon in SLE; however maintaining remission over time is more difficult, since SLE relapses are very common. We should make every effort to achieve and maintain these targets, in fact we know that the longer the remission or the LDA, the lower the damage accrual.^{1–2–5–6} In patients with lupus nephritis (LN) the lack of achievement of EULAR/ERA-EDTA response at 1 year is predictive of a poor renal outcome⁷ and, again, the longer the duration of LN remission the lower the proportion of patients who develop chronic kidney disease.⁸

The second step in the treat-to-target (T2T) strategy should be to minimize or even withdrawal glucocorticoids (GC). The short- and long-term side-effects of GC are very well known. We evaluated the increase in damage progression according to the level of remission in our patients: complete remission, clinical remission off GC, and clinical remission on prednisone ≤ 5 mg/day.² Interestingly, no differences in damage progression were observed among the different levels of remission in patients who achieve < 5 consecutive years remission, by contrast a significant difference was observed in those who achieve ≥ 5 years remission: i.e. patients in clinical remission on prednisone accumulated more damage than those in clinical remission off prednisone or in complete remission.² Thus, to achieve clinical remission is more important than to take a small daily dosage of prednisone in the short term, but in the long term even a small daily dosage of prednisone can contribute to damage progression.²

The third step in the T2T strategy is to reduce and to withdraw immunosuppressants (IS) where possible. In a recent study carried out in the Toronto lupus cohort, univariate and multivariate analysis showed IS as well as GC and other factors were predictors of damage progression within 5 years. We have recently analysed prevalence and predictors of flare after IS discontinuation in SLE patients in remission: Out of 319 patients ever treated with IS, 139 discontinued IS, 105 due to remission and 34 due to poor adherence/intolerance. Twenty-six patients developed a flare, and the flare-free survival was higher in patients who discontinued due to remission than in those who discontinued IS due to poor adherence/intolerance.⁶ The longer the remission before discontinuation and hydroxychloroquine intake were the most significant protective factors.

T2T strategy through the achievement of remission/LDA can improve disease outcomes, especially halting damage accrual. The proportion of patients who can achieve remission and LDA largely depends on the definition used, and in any case is higher in a clinical practice setting than in randomised controlled trials (RCTs). Notably, biologics can help attain remission and LDA and, in turn, dampen damage progression.⁹

Learning Objectives

- Discuss the major targets in SLE management and their timing in a sequential strategy
- Explain the importance of achieving remission or LDA in SLE
- Describe the role of biologics in achieving remission or LDA in post-hoc analysis of RCTs and in clinical practice setting

REFERENCES

1. Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. *Ann Rheum Dis*. 2015;**74**(12):2117–22.
2. Zen M, Iaccarino L, Gatto M, et al. The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients. *Ann Rheum Dis*. 2017;**76**(3):562–5.
3. Gatto M, Zen M, Iaccarino L, Doria A. New therapeutic strategies in systemic lupus erythematosus management. *Nat Rev Rheumatol*. 2019;**15**(1):30–48.
4. Zen M, Iaccarino L, Gatto M, et al. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. *Ann Rheum Dis*. 2018;**77**(1):104–10.
5. Saccon F, Zen M, Gatto M, et al. Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. *Ann Rheum Dis*. 2020;**79**(7):943–50.
6. Zen M, Saccon F, Gatto M, et al. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission. *Rheumatology (Oxford)*. 2020;**59**(7):1591–8.
7. Moroni G, Gatto M, Tamborini F, et al. Lack of EULAR/ERA-EDTA response at 1 year predicts poor long-term renal outcome in patients with lupus nephritis. *Ann Rheum Dis*. 2020;**79**(8):1077–83.
8. Moroni G, Vercelloni PG, Quaglini S, et al. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. *Ann Rheum Dis*. 2018;**77**(9):1318–25.
9. Gatto M, Saccon F, Zen M, et al. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting. *Arthritis Rheumatol*. 2020;**72**(8):1314–24.

17

LUPUS TREATMENT IN THE NEXT DECADE: THE NEXT DECADE IS UPON US

Richard Furie. Zucker School of Medicine at Hofstra/Northwell, New York, USA

10.1136/lupus-2021-la.17

There is little question that our colleagues in rheumatology who treat patients with rheumatoid or psoriatic arthritis have outdone us ‘lupologists’ in bringing new therapies to the community. Biologics have truly been transformative for those patients with inflammatory arthritis. We are now starting to see the same successes in lupus. As we celebrate the 10th anniversary of the FDA approval of belimumab, the lupus community recently witnessed the approval of two drugs, belimumab and voclosporin, for the treatment of lupus nephritis. In addition, several Phase 2 studies yielded favorable results and will be progressing to Phase 3.^{1–5} Drug development activity is currently unprecedented, and there is no doubt that research advances will improve outcomes and ensure brighter futures for our patients with systemic lupus.

Learning Objectives

- Describe unmet needs in SLE treatment
- Discuss biologic targets for SLE drug development
- Explain recent clinical trial results

REFERENCES

1. Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet*. 2018;**392**(10143):222–31.
2. Rovin BH, Solomons N, Pendergraft WF, 3rd, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. *Kidney Int*. 2019;**95**(1):219–31.
3. Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. *J Clin Invest*. 2019;**129**(3):1359–71.
4. Furie R, Rovin BH, Houssiau F, et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. *N Engl J Med*. 2020;**383**(12):1117–28.
5. Morand EF, Furie R, Tanaka Y, et al. Trial of Anifrolumab in Active Systemic Lupus Erythematosus. *N Engl J Med*. 2020;**382**(3):211–21.

Workshop

18

CUTANEOUS LUPUS

¹Bernardo Pons-Estel, ²Annegret Kuhn, ³Andrea Doria. ¹Regional Center for Autoimmune and Rheumatic Diseases and the Cardiovascular Institute of Rosario, Argentina; ²University Hospital Münster, Germany; ³University of Padova, Italy

10.1136/lupus-2021-la.18

Case 1: 35-year-old Mestizo female

Bernardo Pons-Estel

A 35-year-old Mestizo female was diagnosed with systemic lupus erythematosus (SLE) in 2005 based on polyarthritides, malar rash, photosensitivity, mucosal ulcerations, positive ANA and anti-dsDNA, and low complement. She was treated with prednisone 20–30 mg/day and hydroxychloroquine (HCQ) 400 mg/day. In June 2010, lupus pneumonitis was diagnosed.

In July 2018, she was first admitted to our hospital. She was cushingoid and had fever, fatigue, malar rash, oral ulcers, alopecia, polyarthritides, oedema, multiple purplish-red streaks, and active erythematous, palpable and painful subcutaneous indurated nodules/plaques located on her face, proximal lower extremities and abdomen; some were ulcerated.

Laboratory tests RBC 3.8 ($\times 10^{12}/L$), hemoglobin 11.8 g/dL, WBC 2.3 ($\times 10^9/L$), platelets 62 ($\times 10^9/L$), ESR 8 mm, CRP 0.8 mg/L, serum ferritin 1,487 ng/mL, ALAT 70 UI/mL, ASAT 26 UI/mL, GGT 64 U/L, BUN 43 mg/dL, serum creatinine 1.54 mg/dL, GFR 67 mL/min, cholesterol 186 mg/dL, triglycerides 149 mg/dL, proteinuria 210 mg/24 h, ANA 1/320, speckled pattern, anti-Sm (+) and anti-dsDNA, anti-U1RNP, anti-Ro and anti-La all (–). C3 75 mg/dL, C4 10, Coombs test (–), procalcitonin 0.29 ng/mL (<0.5). VDRL and viral serologies were negative. A cutaneous ulcer culture showed *proteus mirabilis*. Her SLEDAI was 19. Three skin biopsies of indurated lesions all showed lobular panniculitis.

She was treated with IV methylprednisolone (500 mg/day/3 days), and high-dose intravenous immunoglobulin, and discharged with mycophenolate mofetil 1 g/day, HCQ 400 mg/day, prednisone 20 mg/day and TMS-SMX 860/160 BID for 5 days. A week later she was re-admitted with fever, pancytopenia, hepatosplenomegaly, lymphadenopathy and several painful, indurated erythematous lesions. Her SLEDAI was 13. A bone marrow aspiration and biopsy was interpreted as a macrophage activated syndrome in the context of SLE exacerbation and treated with IV dexamethasone, colony stimulating factor, and rituximab 1000 mg. Despite treatment, she remained severely ill with fever, asthenia, petechiae and purpura on her abdomen and thighs, and pancytopenia. Due to disease severity, treatment with etoposide was indicated. Finally, the patient presented an acute episode of respiratory distress followed by death.

Discussion Points

- Interpreting the different skin manifestations in a patient with SLE
- Analyzing complications and differential diagnoses with other associated diseases

Case 2: 28-year-old Caucasian female

Annegret Kuhn

A 28-year-old Caucasian female was diagnosed with systemic lupus erythematosus (SLE) in 1996 and presented with severe, erythematous, scarring discoid lesions on the scalp,